CancerPath helps international patients access GC101 — a breakthrough TIL cell therapy clinical trial showing 41.7% response rates in advanced lung cancer, with no major toxicity.
TIL (Tumor-Infiltrating Lymphocyte) therapy uses your own immune cells — already trained to recognize your tumor — amplified millions of times and returned to fight the cancer.
TIL cells live inside your tumor. Unlike CAR-T or checkpoint inhibitors, they're already sensitized to your specific cancer's antigens — no genetic engineering required.
Traditional TIL requires intensive chemotherapy and high-dose IL-2 injections. GC101 eliminates both — making it safer, more accessible, and suitable for patients who couldn't tolerate conventional TIL.
A single IV infusion. Multiple patients have achieved complete tumor clearance (CR), with the longest tumor-free survival exceeding 4 years and counting.
Each GC101 and GC203 clinical trial is led by a leading Chinese oncologist with international recognition in their field.
MD, PhD — Thoracic Oncology
Shanghai Chest Hospital
PI, MIZAR-005 — GC101 in advanced NSCLC
MD, PhD — Melanoma & Sarcoma
Peking University Cancer Hospital
PI, MIZAR-003 — GC101 in advanced melanoma
MD, PhD — Gynecologic Oncology
Fudan University Shanghai Cancer Center
PI, GC203 — TIL therapy for ovarian cancer
Developed by Juncell Therapeutics, GC101 is the world's first natural TIL therapy without high-intensity lymphodepletion or IL-2 administration.
Eliminates the severe toxicity associated with traditional TIL protocols
No donor-derived support cells needed in manufacturing
Natural TIL — no virus-mediated engineering, lower biosafety concerns
Only mild conditioning required before infusion — no aggressive chemo
No requirement for intensive care unit or specialized isolation room
No follow-up IL-2 injections needed after cell infusion
GC101 has shown responses across multiple solid tumors. Active clinical trials are recruiting now.
For patients who have failed PD-1 therapy. Multi-center randomized trial at top institutions including Peking University Cancer Hospital.
For patients who have failed targeted therapy + platinum chemotherapy, or PD-(L)1 + platinum chemo. PI: Prof. Lu Shun, Shanghai Chest Hospital.
GC203 (gene-modified TIL) showing promising results in multi-line treatment failures. Eligible patients can enquire.
Including cervical cancer, endometrial cancer, pancreatic cancer, and glioblastoma. Clinical cases with objective responses documented.
From first contact to cell infusion, here's a realistic picture of the timeline and logistics involved.
Complete our online screener or contact us directly. We review your diagnosis, treatment history, and current status to assess whether you meet clinical trial criteria.
Remote / onlineIf eligible, Juncell's clinical team reviews your case. You'll need to provide recent imaging, blood work, pathology, and treatment history. Enrollment is at no cost.
Remote document submissionA minimally invasive biopsy procedure is performed at the lead trial center in Shanghai to collect tumor tissue. This is the source material for manufacturing your TIL cells. Stay: approximately 3–5 days.
Trip 1 — ShanghaiYour tumor tissue is transported to Juncell's GMP manufacturing facility. TIL cells are expanded from millions to billions over approximately 4–6 weeks. You return home during this period.
Wait at homeYou return to China for mild pre-conditioning chemotherapy, followed by IV infusion of your TIL cells. Hospital stay: approximately 2–3 weeks in Hainan Boao.
Trip 2 — HainanFirst imaging assessment at 6 weeks post-infusion. Follow-up assessments every 6 weeks. Remote follow-up can often be coordinated with your home oncologist.
Mostly remoteAnswer 7 quick questions to find out if you or your loved one may qualify for GC101 clinical trials. Takes about 2 minutes.
These are published clinical cases from Juncell's ongoing trials — not anecdotes, but formally assessed outcomes.
Patient had failed PD-1 monotherapy and dual immunotherapy. Foot lesion reduced 36%, lung lesion reduced 47.4%, abdominal lesion reduced 31.7%. No major adverse events — only mild rash and fever, resolved with standard treatment.
Partial response (PR)Phase Ib data from MIZAR-005 predecessor. 12-month overall survival rate 66.7% with median OS not yet reached at 13 months follow-up. DCR 66.7%.
Phase Ib cohort dataDocumented case from investigator-initiated study. Single infusion without IL-2 or intensive conditioning. Tumor undetectable on imaging at 4-week assessment.
Complete response (CR)If you'd like a personal conversation before filling out any form, just email us. We respond within 48 hours and can arrange a call in English, French, or Mandarin.
CancerPath is an independent patient advisory service. We are not a healthcare provider and do not give medical advice. All treatment decisions should be made with your oncologist.
A CancerPath advisor will review your information and be in touch within 48 hours. Please check your spam folder if you don't hear from us.